Novo Nordisk A/S
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 77,406
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Novo Alle 1 Bagsvaerd Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued -- GF Score: 76/100
Microsoft to invest $2.5B in new AI implementation business
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Citi says Wegovy pill outpacing rivals as oral GLP-1 race heats up
My Top 10 High-Yield Picks For July 2026: One Yields More Than 13%
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
Novo's top US exec wants more insurance coverage for weight-loss drugs
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch
Novo Nordisk: A Strong Yield And Continued Growth
Bank sees structural strength in GLP-1 market as obesity drives demand
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push